CANxx – An IL1RAP-based antibody platform
CANxx consolidates Cantargia’s strong position for the future
Cantargia is a leading company in the development of therapeutics targeting IL1RAP and has built up a knowledge and technology platform within this area.
Within CANxx, Cantargia has developed over 100 unique antibodies that bind to IL1RAP with different properties. The CANxx antibody library enables Cantargia to rapidly develop novel antibody-based therapies with properties that can be used for treatment of various diseases.
The development of new therapeutics also depends on analysis and diagnostics, and CANxx is a source of antibodies also for these purposes.